MILAN (Reuters) – An investment by NB Renaissance in Neopharmed that will see the private equity firm share with Ardian majority ownership of the Italian pharmaceutical group values the latter at 1.4-1.5 billion euros ($1.4-$1.5 billion), two people close to the deal said. NB Renaissance, which has a track record in Italy’s pharmaceutical sector having invested in the past in Bologna-based AlfaSigma, won a beauty contest to partner with Ardian and Neopharmed’s original shareholders, the Del Bono family. NB Renaissance was advised by JPMorgan. A vehicle owned in equal parts by Ardian and NB Ren…